We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Guidelines for Blood Pressure Medication

By HospiMedica staff writers
Posted on 07 Aug 2006
Family doctors in the United Kingdom (UK) are being advised not to prescribe beta-blockers as the routine therapy for high blood pressure but to favor other treatments.

The new guidelines were issued by the National Health Service (NHS, London, UK) following advice from the National Institute for Health and Clinical Excellence (NICE, London, UK) which noted that other drugs are better at treating hypertension. More...
These include calcium channel blockers, diuretics, and angiotensin-converting enzyme (ACE) inhibitors, used to regulate the hormonal system and open up blood vessels. The new guidelines are based on research showing that the newer drugs used to treat high blood pressure cut the risk of heart attacks and strokes by half when compared to older treatments.

For patients under 55, the guidelines recommend that the first medication choice should be an ACE inhibitor, followed by a calcium channel blocker or a diuretic, then all three. For patients over 55, or black patients, first choice should be a calcium channel blocker or diuretic, followed by an ACE inhibitor, and then all three if necessary. Beta-blockers should no longer be used for hypertension, except in patients who also need them for other reasons such as heart failure.

Currently, as many as two million people take beta-blockers in the United Kingdom, although patients who take the drugs for conditions such as angina and anxiety will be unaffected by the new guidelines.



Related Links:
National Health Service

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.